EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MARCH 3, 2020
Media advisory: The full study and related articles are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.1166?guestAccessKey=07d020ad-9f38-428b-a798-714d5affb7dc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=030320
What The Study Did: Researchers estimated the cost to bring 63 new drugs or biologics to market between 2009 and 2018 using publicly available data on research and development expenditures for these medicines. This study is part of a theme issue from JAMA on drug pricing.
Authors: Olivier J. Wouters, Ph.D., of the London School of Economics and Political Science, is the corresponding author.
Editor’s Note: The article includes conflict of interest disclosures. Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.